Gracell Biotechnologies Reports Fourth Quarter and Full Year 2022 Unaudited Financial Results, and Provides Corporate Update
13 mars 2023 07h30 HE
|
Gracell Biotechnologies Inc.
Plan to commence Phase 1b/2 clinical trial in US evaluating FasTCAR-T GC012F for the treatment of relapsed/refractory multiple myeloma (RRMM) in the second quarter of 2023 after receipt of FDA...
Gracell Biotechnologies to Participate in Two Upcoming Investor Conferences
14 févr. 2023 08h46 HE
|
Gracell Biotechnologies Inc.
SAN DIEGO, Calif., and SUZHOU, China and SHANGHAI, China, Feb. 14, 2023 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. ("Gracell" or the "Company", NASDAQ: GRCL), a global...
Gracell Biotechnologies Reports Third Quarter 2022 Unaudited Financial Results and Provides Corporate Update
14 nov. 2022 07h15 HE
|
Gracell Biotechnologies Inc.
On track to submit IND filings in U.S. and China for GC012F for the treatment of relapsed/refractory multiple myeloma (RRMM) in the fourth quarter 2022First clinical data from ongoing...
Gracell Biotechnologies Reports Second Quarter 2022 Unaudited Financial Results and Provides Corporate Update
15 août 2022 07h15 HE
|
Gracell Biotechnologies Inc.
Presented updated clinical data from an investigator-initiated trial (IIT) evaluating FasTCAR GC012F for the treatment of relapsed/refractory multiple myeloma (r/r MM) at ASCO and EHA 2022, which...
Gracell Biotechnologies Reports First Quarter 2022 Unaudited Financial Results and Provides Corporate Update
16 mai 2022 07h30 HE
|
Gracell Biotechnologies Inc.
Presented early clinical data from a first-in-human Phase 1 investigator-initiated trial (IIT) of allogeneic TruUCAR candidate GC502 for relapsed/refractory B-cell acute lymphoblastic leukemia (r/r...
Gracell Biotechnologies to Participate in Three Investor Conferences in May
04 mai 2022 08h30 HE
|
Gracell Biotechnologies Inc.
SAN DIEGO and SUZHOU, China and SHANGHAI, China, May 04, 2022 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company...
Gracell Biotechnologies to Report First Quarter 2022 Financial Results on Monday, May 16, 2022
02 mai 2022 08h00 HE
|
Gracell Biotechnologies Inc.
SAN DIEGO, Calif., and SUZHOU, China, May 02, 2022 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company dedicated to...
Gracell Biotechnologies Announces Filing of Its Annual Report on Form 20-F for Fiscal Year 2021
22 avr. 2022 17h00 HE
|
Gracell Biotechnologies Inc.
SAN DIEGO, Calif. and SUZHOU, China, April 22, 2022 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company dedicated to...
Gracell Biotechnologies to Participate in Three Investor Conferences in April
29 mars 2022 08h30 HE
|
Gracell Biotechnologies Inc.
PALO ALTO, Calif. and SUZHOU, China, March 29, 2022 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company dedicated to...
Gracell Biotechnologies Reports Fourth Quarter and Full Year 2021 Unaudited Financial Results and Provides Corporate Update
14 mars 2022 07h30 HE
|
Gracell Biotechnologies Inc.
Plan to file U.S. IND for lead program FasTCAR-T GC012F for relapse and/or refractory multiple myeloma (RRMM) during second half of 2022Allogeneic TruUCAR-T GC502 currently being investigated in a...